Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Industry Pleased With Brexit Committee's Focus On Regulation

Executive Summary

Industry group ABPI is focusing on the fact that the report from parliamentarians on the cross-party Exiting the EU Committee has made at least some mention of the need to ensure that medicines regulation is ready for Brexit on “day one.”

You may also be interested in...

UK QPPVs Fear Brexit Could Seriously Threaten Their Role In Pharmacovigilance

UK based QPPVs are worried about the direct and tangible impact of Brexit on their current jobs, fearing that the QPPV role may either completely vanish from the UK or have its authority undermined.

Post-Brexit UK Could Be ‘Back Of The Queue’ For Drug Access, Warns MHRA Chair

Professor Sir Michael Rawlins, chair of the MHRA, has told a UK committee of his concerns over Brexit, including possible delays in access to new drugs, a decline in revenues for regulatory work on behalf of the EU, and the possibility that some firms’ HQs might follow the European Medicines Agency if it relocates to another European country.

Brexit: EMA Could Lose Up To Half Its Staff If It Has To Move

The European Medicines Agency is working to ensure it can cope with the many challenges it will face as a result of the UK leaving the EU. Those challenges could include the agency losing 50% of its staff, according to the EMA’s deputy head Noel Wathion.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts